Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer
All cases at the participating institutions.
Observational Model: Case-Only, Time Perspective: Prospective
The nature, incidence, duration, and severity of adverse events; discontinuation due to adverse events; outcome and causality will be monitored in this study.
adjuvant 1 year ; advanced 6 years
Pfizer CT.gov Call Center
Korea: Food and Drug Administration